Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade, Dexamethasone, and Zometa in Relapsed Multiple Myeloma
NCT00972959Phase 2
Key facts
- Status
- Completed
- Start
- Jul 2009
- Primary completion
- May 2013
- Countries
- 1
- Sponsor
- National and Kapodistrian University of Athens
- Drugs
- bortezomib
- Conditions
- multiple myeloma (MM)
01
Overview
Phase 2, open-label trial of bortezomib in multiple myeloma (MM), sponsored by National and Kapodistrian University of Athens. Started Jul 2009; status: completed.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Who it enrols
Post-menopausal women with relapsed multiple myeloma (1-3 prior lines) and adequate organ function.
04
Registry description
The aim of this study is to evaluate the effect of bortezomib in combination with dexamethasone and zoledronic acid on bone mineral density (BMD) and skeletal related events (SREs) in Patients with Multiple Myeloma who Have Relapsed after 1-3 Prior Lines of Therapy
Beyond the preview
Go deeper on NCT00972959.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00972959.